Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6184703 | Gynecologic Oncology | 2016 | 6 Pages |
Abstract
The MTD of veliparib combined with CD is 80Â mg p.o. b.i.d. in women with recurrent, platinum-sensitive ovarian cancer. With bevacizumab, DLTs were noted in 9 out of 12 patients. Lower doses of veliparib will need to be considered when given in combination with platinum-based therapies.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Lisa M. Landrum, William E. Brady, Deborah K. Armstrong, Kathleen N. Moore, Paul A. DiSilvestro, David M. O'Malley, Meaghan E. Tenney, Peter G. Rose, Paula M. Fracasso,